Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
1.
J Sci Food Agric ; 103(3): 1550-1560, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36208473

ABSTRACT

BACKGROUND: Lipopolysaccharides (LPS) are the main pathogenic substances in Gram-negative bacteria. The aim of this study was to investigate the preventive effects of dietary curcumin (CUR) on LPS toxicity in the duck ileum. The duck diet was supplemented with CUR (0.5 g kg-1 ) for 28 days, while the birds were injected with LPS (0.5 mg kg-1 body weight per injection, administered as seven injections in the last week of the experimental period). RESULTS: LPS significantly decreased the ileal villus-to-crypt ratio in the non-supplemented CUR group. Dietary CUR alleviated LPS-induced morphological damage to the ileum. Moreover, dietary CUR alleviated oxidative stress by increasing the levels of total superoxide dismutase (T-SOD) (P < 0.05) and glutathione S-transferase (GST) (P < 0.05) and decreasing the production of malonic dialdehyde (MDA) (P < 0.05) in control ducks and LPS-challenged ducks. Dietary CUR significantly inhibited the LPS-induced massive production of inflammatory factors (IL-1ß, IL-6, and TNF-α) (P < 0.05). CUR induced the inhibition of TLR4 and activation of Nrf2 to reduce the expression of inflammation-related genes (TLR4, NF-κB, IKK, TXNIP, NLRP3, caspase-1, IL-1ß, IL-6, and TNF-α). Moreover, dietary CUR ameliorated the decrease in claudin-1 and occludin expression (P < 0.05) and improved ZO-1 expression in the duck ileum (P < 0.05). CONCLUSION: In conclusion, dietary CUR has beneficial effects on LPS-induced ileal damage, oxidative damage, and inflammatory response by inhibiting the TLR/NF-κB and activating the Nrf2 signaling pathways in ducks. This study provides valuable information regarding the therapeutic uses of CUR in duck ileitis. © 2022 Society of Chemical Industry.


Subject(s)
Curcumin , Ileitis , Animals , Lipopolysaccharides/adverse effects , Ducks/metabolism , Curcumin/pharmacology , Curcumin/therapeutic use , NF-kappa B/metabolism , Tumor Necrosis Factor-alpha/metabolism , Interleukin-6/metabolism , NF-E2-Related Factor 2/genetics , NF-E2-Related Factor 2/metabolism , Toll-Like Receptor 4/metabolism , Toll-Like Receptor 4/therapeutic use , Inflammation/chemically induced , Inflammation/drug therapy , Inflammation/prevention & control , Oxidative Stress , Ileitis/chemically induced , Ileitis/genetics , Ileitis/prevention & control
2.
J Crohns Colitis ; 16(6): 978-991, 2022 Jul 14.
Article in English | MEDLINE | ID: mdl-34893805

ABSTRACT

BACKGROUND AND AIMS: Crohn's disease is a debilitating chronic inflammatory disorder of the mammalian gastrointestinal tract. Current interventions using anti-tumour necrosis factor [anti-TNF] biologics show long-term benefit in only half of patients. This study focused on the role of the TNF receptor 1 [TNFR1] in pathogenesis in a TNF-driven model of ileitis. METHODS: We studied TNFΔAU-rich element [ARE]/+ [TNFdARE] mice, which develop progressive ileitis similar to Crohn's ileitis. Histopathological analysis and gene expression profiling were used to characterize disease progression from 5 to 16 weeks. Mice with TNFR1 hemizygosity [TNFdARE/R1het] allowed us to assess gene dosage effects. Transcriptional profiling established inflection points in disease progression; inflammatory gene expression increased at 8 weeks with a plateau by 10 weeks, so these were selected as endpoints of treatment using the TNF biologic infliximab and the TNFR1-specific XPro1595. Differences in recruitment of cells in the lamina propria were assessed using flow cytometry. RESULTS: TNFdARE/R1het mice displayed stable long-term protection from disease, associated with decreased recruitment of CD11bhiF4/80lo monocytes and CD11bhiLy6Ghi neutrophils, suggesting an important role of TNFR1 signalling in pathogenesis, and indicating potential benefit from TNFR1-specific intervention. Treatment with infliximab and XPro1595 both showed a similar impact on disease in TNFdARE mice. Importantly, these beneficial effects were greatly surpassed by hemizygosity at the TNFR1 locus. CONCLUSIONS: Treatment with either infliximab or XPro1595 produced moderate protection from ileitis in TNFdARE mice. However, hemizygosity at the TNFR1 locus in TNFdARE mice showed far better protection, implicating TNFR1 signalling as a key mediator of TNF-driven disease.


Subject(s)
Crohn Disease , Ileitis , Animals , Crohn Disease/complications , Disease Progression , Ileitis/drug therapy , Ileitis/etiology , Ileitis/prevention & control , Infliximab/pharmacology , Infliximab/therapeutic use , Mammals/metabolism , Mice , Receptors, Tumor Necrosis Factor, Type I/genetics , Tumor Necrosis Factor Inhibitors , Tumor Necrosis Factor-alpha/metabolism
3.
J Nutr ; 151(3): 579-590, 2021 03 11.
Article in English | MEDLINE | ID: mdl-33484150

ABSTRACT

BACKGROUND: The current nutritional composition of the "American diet" (AD; also known as Western diet) has been linked to the increasing incidence of chronic diseases, including inflammatory bowel disease (IBD), namely Crohn disease (CD). OBJECTIVES: This study investigated which of the 3 major macronutrients (protein, fat, carbohydrates) in the AD has the greatest impact on preventing chronic inflammation in experimental IBD mouse models. METHODS: We compared 5 rodent diets designed to mirror the 2011-2012 "What We Eat in America" NHANES. Each diet had 1 macronutrient dietary source replaced. The formulated diets were AD, AD-soy-pea (animal protein replaced by soy + pea protein), AD-CHO ("refined carbohydrate" by polysaccharides), AD-fat [redistribution of the ω-6:ω-3 (n-6:n-3) PUFA ratio; ∼10:1 to 1:1], and AD-mix (all 3 "healthier" macronutrients combined). In 3 separate experiments, 8-wk-old germ-free SAMP1/YitFC mice (SAMP) colonized with human gut microbiota ("hGF-SAMP") from CD or healthy donors were fed an AD, an AD-"modified," or laboratory rodent diet for 24 wk. Two subsequent dextran sodium sulfate-colitis experiments in hGF-SAMP (12-wk-old) and specific-pathogen-free (SPF) C57BL/6 (20-wk-old) mice, and a 6-wk feeding trial in 24-wk-old SPF SAMP were performed. Intestinal inflammation, gut metagenomics, and MS profiles were assessed. RESULTS: The AD-soy-pea diet resulted in lower histology scores [mean ± SD (56.1% ± 20.7% reduction)] in all feeding trials and IBD mouse models than did other diets (P < 0.05). Compared with the AD, the AD-soy-pea correlated with increased abundance in Lactobacillaceae and Leuconostraceae (1.5-4.7 log2 and 3.0-5.1 log2 difference, respectively), glutamine (6.5 ± 0.8 compared with 3.9 ± 0.3 ng/µg stool, P = 0.0005) and butyric acid (4:0; 3.3 ± 0.5 compared with 2.54 ± 0.4 ng/µg stool, P = 0.006) concentrations, and decreased linoleic acid (18:2n-6; 5.4 ± 0.4 compared with 8.6 ± 0.3 ng/µL plasma, P = 0.01). CONCLUSIONS: Replacement of animal protein in an AD by plant-based sources reduced the severity of experimental IBD in all mouse models studied, suggesting that similar, feasible adjustments to the daily human diet could help control/prevent IBD in humans.


Subject(s)
Dietary Proteins/administration & dosage , Gastrointestinal Microbiome/physiology , Glycine max , Ileitis/prevention & control , Pisum sativum , Amino Acids/chemistry , Amino Acids/metabolism , Animal Feed , Animals , Bacteroidetes , Colitis/chemically induced , Colitis/prevention & control , Dextran Sulfate , Diet/veterinary , Dietary Carbohydrates , Dietary Fats , Feces/chemistry , Female , Firmicutes , Humans , Male , Mice , Mice, Inbred C57BL , Specific Pathogen-Free Organisms
4.
Cell Death Differ ; 27(1): 161-175, 2020 01.
Article in English | MEDLINE | ID: mdl-31101885

ABSTRACT

The kinase RIP1 acts in multiple signaling pathways to regulate inflammatory responses and it can trigger both apoptosis and necroptosis. Its kinase activity has been implicated in a range of inflammatory, neurodegenerative, and oncogenic diseases. Here, we explore the effect of inhibiting RIP1 genetically, using knock-in mice that express catalytically inactive RIP1 D138N, or pharmacologically, using the murine-potent inhibitor GNE684. Inhibition of RIP1 reduced collagen antibody-induced arthritis, and prevented skin inflammation caused by mutation of Sharpin, or colitis caused by deletion of Nemo from intestinal epithelial cells. Conversely, inhibition of RIP1 had no effect on tumor growth or survival in pancreatic tumor models driven by mutant Kras, nor did it reduce lung metastases in a B16 melanoma model. Collectively, our data emphasize a role for the kinase activity of RIP1 in certain inflammatory disease models, but question its relevance to tumor progression and metastases.


Subject(s)
Inflammation/enzymology , Neoplasms/enzymology , Receptor-Interacting Protein Serine-Threonine Kinases/antagonists & inhibitors , Animals , Arthritis/enzymology , Cell Death , Cell Line , Cell Line, Tumor , Colitis/etiology , Colitis/prevention & control , Dermatitis/enzymology , Female , Gene Knock-In Techniques , Humans , Ileitis/etiology , Ileitis/prevention & control , Intracellular Signaling Peptides and Proteins/genetics , Male , Melanoma, Experimental/pathology , Mice , Neoplasm Metastasis , Pancreatic Neoplasms/pathology , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Rats , Receptor-Interacting Protein Serine-Threonine Kinases/genetics , Receptor-Interacting Protein Serine-Threonine Kinases/physiology
5.
Front Immunol ; 10: 442, 2019.
Article in English | MEDLINE | ID: mdl-30936867

ABSTRACT

Background and aims: Mice orally infected with T. gondii develop Crohn's disease (CD)-like enteritis associated with severe mucosal damage and a systemic inflammatory response, resulting in high morbidity and mortality. Previously, helminthic infections have shown therapeutic potential in experimental colitis. However, the role of S. mansoni in T. gondii-induced CD-like enteritis has not been elucidated. Our study investigated the mechanisms underlying T. gondii-induced ileitis and the potential therapeutic effect of S. mansoni coinfection. Methods: C57BL/6 mice were infected by subcutaneous injection of cercariae of the BH strain of S. mansoni, and 7-9 weeks later, they were orally infected with cysts of the ME49 strain of T. gondii. After euthanasia, the ileum was removed for histopathological analysis; staining for goblet cells; immunohistochemistry characterizing mononuclear cells, lysozyme expression, apoptotic cells, and intracellular pathway activation; and measuring gene expression levels by real-time PCR. Cytokine concentrations were measured in the serial serum samples and culture supernatants of the ileal explants, in addition to myeloperoxidase (MPO) activity. Results:T. gondii-monoinfected mice presented dense inflammatory cell infiltrates and ulcerations in the terminal ileum, with abundant cell extrusion, apoptotic bodies, and necrosis; these effects were absent in S. mansoni-infected or coinfected animals. Coinfection preserved goblet cells and Paneth cells, remarkably depleted in T. gondii-infected mice. Densities of CD4- and CD11b-positive cells were increased in T. gondii- compared to S. mansoni-infected mice and controls. MPO was significantly increased among T. gondii-mice, while attenuated in coinfected animals. In T. gondii-infected mice, the culture supernatants of the explants showed increased concentrations of TNF-alpha, IFN-gamma, and IL-17, and the ileal tissue revealed increased expression of the mRNA transcripts for IL-1 beta, NOS2, HMOX1, MMP3, and MMP9 and activation of NF-kappa B and p38 MAPK signaling, all of which were counterregulated by S. mansoni coinfection. Conclusion:S. mansoni coinfection attenuates T. gondii-induced ileitis by preserving mucosal integrity and downregulating the local inflammatory response based on the activation of NF-kappa B and MAPK. The protective function of prior S. mansoni infection suggests the involvement of innate immune mechanisms and supports a conceptually new approach to the treatment of chronic inflammatory diseases, including CD.


Subject(s)
Coinfection/immunology , Ileitis/prevention & control , Intestinal Mucosa/physiopathology , Schistosomiasis mansoni/immunology , Therapy with Helminths , Toxoplasmosis, Animal/therapy , Animals , Apoptosis , Crohn Disease/therapy , Cytokines/blood , Disease Models, Animal , Down-Regulation , Epithelium/physiology , Gene Expression Profiling , Ileitis/etiology , Ileitis/immunology , Ileitis/pathology , MAP Kinase Signaling System/physiology , Mice , Mice, Inbred C57BL , NF-kappa B/metabolism , Peroxidase/blood , Systemic Inflammatory Response Syndrome/etiology , Systemic Inflammatory Response Syndrome/immunology , Toxoplasmosis, Animal/complications , Toxoplasmosis, Animal/immunology
6.
Inflamm Bowel Dis ; 25(1): 14-26, 2019 01 01.
Article in English | MEDLINE | ID: mdl-30295722

ABSTRACT

Background: TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain-receptor-3 (DR3), are multifunctional mediators of effector and regulatory immunity. We aimed to evaluate the functional role and therapeutic potential of TL1A/DR3 signaling in Crohn's disease-like ileitis. Methods: Ileitis-prone SAMP1/YitFc (SAMP) and TNFΔARE/+ mice were rendered deficient for DR3 or TL1A by microsatellite marker-assisted backcrossing. Pathological and immunological characteristics were compared between control and knockout mice, and mucosal immunophenotype was analyzed by Nanostring microarray assay. The therapeutic effect of pharmacological TL1A neutralization was also investigated. Results: DR3 deficiency was associated with restoration of a homeostatic mucosal immunostat in SAMP mice through the regulation of several pro- and anti-inflammatory genes. This led to suppression of effector immunity, amelioration of ileitis severity, and compromised ability of either unfractionated CD4+ or CD4+CD45RBhi mucosal lymphocytes to transfer ileitis to severe combined immunodeficient mice recipients. TNF-driven ileitis was also prevented in TNFΔARE/+xDR3-/- mice, in association with decreased expression of the pro-inflammatory cytokines TNF and IFN-γ. In contrast to DR3, TL1A was dispensable for the development of ileitis although it affected the kinetics of inflammation, as TNFΔARE/+xTL1A-/- demonstrated delayed onset of inflammation, whereas administration of a neutralizing, anti-TL1A antibody ameliorated early but not late TNFΔARE/+ ileitis. Conclusion: We found a prominent pro-inflammatory role of DR3 in chronic ileitis, which is only partially mediated via interaction with TL1A, raising the possibility for additional DR3 ligands. Death-domain-receptor-3 appears to be a master regulator of mucosal homeostasis and inflammation and may represent a candidate therapeutic target for chronic inflammatory conditions of the bowel.


Subject(s)
Crohn Disease/complications , Gene Expression Regulation , Ileitis/prevention & control , Inflammation/prevention & control , Receptors, Tumor Necrosis Factor, Member 25/physiology , Tumor Necrosis Factor Ligand Superfamily Member 15/physiology , Tumor Necrosis Factor-alpha/physiology , Animals , Antibodies, Monoclonal/pharmacology , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Ileitis/etiology , Inflammation/etiology , Inflammation Mediators/metabolism , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, SCID , T-Lymphocytes, Regulatory/drug effects , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism
7.
Microb Cell Fact ; 16(1): 27, 2017 Feb 13.
Article in English | MEDLINE | ID: mdl-28193209

ABSTRACT

BACKGROUND: Mucositis is one of the most relevant gastrointestinal inflammatory conditions in humans, generated by the use of chemotherapy drugs, such as 5-fluoracil (5-FU). 5-FU-induced mucositis affects 80% of patients undergoing oncological treatment causing mucosal gut dysfunctions and great discomfort. As current therapy drugs presents limitations in alleviating mucositis symptoms, alternative strategies are being pursued. Recent studies have shown that the antimicrobial pancreatitis-associated protein (PAP) has a protective role in intestinal inflammatory processes. Indeed, it was demonstrated that a recombinant strain of Lactococcus lactis expressing human PAP (LL-PAP) could prevent and improve murine DNBS-induced colitis, an inflammatory bowel disease (IBD) that causes severe inflammation of the colon. Hence, in this study we sought to evaluate the protective effects of LL-PAP on 5-FU-induced experimental mucositis in BALB/c mice as a novel approach to treat the disease. RESULTS: Our results show that non-recombinant L. lactis NZ9000 have antagonistic activity, in vitro, against the enteroinvasive gastrointestinal pathogen L. monocytogenes and confirmed PAP inhibitory effect against Opportunistic E. faecalis. Moreover, L. lactis was able to prevent histological damage, reduce neutrophil and eosinophil infiltration and secretory Immunoglobulin-A in mice injected with 5-FU. Recombinant lactococci carrying antimicrobial PAP did not improve those markers of inflammation, although its expression was associated with villous architecture preservation and increased secretory granules density inside Paneth cells in response to 5-FU inflammation. CONCLUSIONS: We have demonstrated for the first time that L. lactis NZ9000 by itself, is able to prevent 5-FU-induced intestinal inflammation in BALB/c mice. Moreover, PAP delivered by recombinant L. lactis strain showed additional protective effects in mice epithelium, revealing to be a promising strategy to treat intestinal mucositis.


Subject(s)
Antigens, Neoplasm/genetics , Antigens, Neoplasm/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Ileitis/prevention & control , Lactococcus lactis/genetics , Lactococcus lactis/physiology , Lectins, C-Type/genetics , Lectins, C-Type/metabolism , Mucositis/prevention & control , Animals , Antibiosis , Antigens, Neoplasm/pharmacology , Biomarkers, Tumor/pharmacology , Disease Models, Animal , Enterococcus faecalis/physiology , Fluorouracil , Humans , Ileitis/chemically induced , Ileitis/drug therapy , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/prevention & control , Intestinal Mucosa/metabolism , Intestine, Small/immunology , Intestine, Small/microbiology , Intestine, Small/pathology , Lactococcus lactis/metabolism , Listeria monocytogenes/physiology , Mice , Mice, Inbred BALB C , Mucositis/chemically induced , Mucositis/drug therapy , Mucositis/microbiology , Pancreatitis-Associated Proteins
8.
Am J Physiol Gastrointest Liver Physiol ; 306(9): G779-87, 2014 May 01.
Article in English | MEDLINE | ID: mdl-24627567

ABSTRACT

Necrotizing enterocolitis (NEC) is associated with a high morbidity and mortality in very low birth weight infants. Several hypotheses regarding the pathogenesis of NEC have been proposed but to date no effective treatment is available. Previous studies suggest that probiotic supplementation is protective. We recently reported that probiotic (Bifidobacterium infantis) conditioned medium (PCM) has an anti-inflammatory effect in cultured fetal human intestinal cells (H4) and fetal intestine explants. In this study, we tested in vivo whether PCM protects neonatal mice from developing intestinal inflammation induced by exposure to Cronobacter sakazakii (C. sakazakii), an opportunistic pathogen associated with NEC. We found that infected neonatal mice had a significantly lower body weight than control groups. Infection led to ileal tissue damage including villous rupture, disruption of epithelial cell alignment, intestinal inflammation, apoptotic cell loss, and decreased mucus production. Pretreatment with PCM prevented infection caused decrease in body weight, attenuated enterocyte apoptotic cell death, mitigated reduced mucin production, and maintained ileal structure. Infected ileum expressed reduced levels of IκBα, which could be restored upon pretreatment with PCM. We also observed a nuclear translocation of NF-κB p65 in H4 cells exposed to C. sakazakii, which was prevented in PCM-pretreated cells. Finally, treatment of neonatal mice with PCM prior to infection sustained the capacity of ileal epithelial proliferation. This study suggests that an active component(s) released into the culture medium by B. infantis may prevent ileal damage by a pathogen linked to NEC.


Subject(s)
Bifidobacterium/metabolism , Cronobacter sakazakii/pathogenicity , Culture Media, Conditioned/pharmacology , Enterobacteriaceae Infections/prevention & control , Enterocolitis, Necrotizing/prevention & control , Ileitis/prevention & control , Ileum/microbiology , Probiotics/pharmacology , Active Transport, Cell Nucleus , Animals , Animals, Newborn , Apoptosis , Bifidobacterium/classification , Body Weight , Cell Line , Cell Proliferation , Disease Models, Animal , Enterobacteriaceae Infections/metabolism , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae Infections/pathology , Enterocolitis, Necrotizing/metabolism , Enterocolitis, Necrotizing/microbiology , Enterocolitis, Necrotizing/pathology , Enterocytes/microbiology , Enterocytes/pathology , Humans , I-kappa B Proteins/metabolism , Ileitis/metabolism , Ileitis/microbiology , Ileitis/pathology , Ileum/metabolism , Ileum/pathology , Mice , Mice, Inbred C57BL , Mucins/metabolism , NF-KappaB Inhibitor alpha , Transcription Factor RelA/metabolism
9.
Gastroenterology ; 146(2): 484-96.e4, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24161699

ABSTRACT

BACKGROUND & AIMS: Rifaximin is used to treat patients with functional gastrointestinal disorders, but little is known about its therapeutic mechanism. We propose that rifaximin modulates the ileal bacterial community, reduces subclinical inflammation of the intestinal mucosa, and improves gut barrier function to reduce visceral hypersensitivity. METHODS: We induced visceral hyperalgesia in rats, via chronic water avoidance or repeat restraint stressors, and investigated whether rifaximin altered the gut microbiota, prevented intestinal inflammation, and improved gut barrier function. Quantitative polymerase chain reaction (PCR) and 454 pyrosequencing were used to analyze bacterial 16S ribosomal RNA in ileal contents from the rats. Reverse transcription, immunoblot, and histologic analyses were used to evaluate levels of cytokines, the tight junction protein occludin, and mucosal inflammation, respectively. Intestinal permeability and rectal sensitivity were measured. RESULTS: Water avoidance and repeat restraint stress each led to visceral hyperalgesia, accompanied by mucosal inflammation and impaired mucosal barrier function. Oral rifaximin altered the composition of bacterial communities in the ileum (Lactobacillus species became the most abundant) and prevented mucosal inflammation, impairment to intestinal barrier function, and visceral hyperalgesia in response to chronic stress. Neomycin also changed the composition of the ileal bacterial community (Proteobacteria became the most abundant species). Neomycin did not prevent intestinal inflammation or induction of visceral hyperalgesia induced by water avoidance stress. CONCLUSIONS: Rifaximin alters the bacterial population in the ileum of rats, leading to a relative abundance of Lactobacillus. These changes prevent intestinal abnormalities and visceral hyperalgesia in response to chronic psychological stress.


Subject(s)
Gastrointestinal Agents/pharmacology , Hyperalgesia/prevention & control , Ileitis/prevention & control , Ileum/drug effects , Intestinal Mucosa/drug effects , Microbiota/drug effects , Rifamycins/pharmacology , Administration, Oral , Animals , Biomarkers/metabolism , Blotting, Western , Cytokines/metabolism , DNA, Bacterial/analysis , Drug Administration Schedule , Gastrointestinal Agents/therapeutic use , Hyperalgesia/etiology , Hyperalgesia/metabolism , Hyperalgesia/microbiology , Ileitis/etiology , Ileitis/metabolism , Ileitis/microbiology , Ileum/metabolism , Ileum/microbiology , Immunohistochemistry , Intestinal Mucosa/metabolism , Intestinal Mucosa/microbiology , Male , Microbiota/genetics , Neomycin/pharmacology , Neomycin/therapeutic use , Occludin/metabolism , Rats , Rats, Wistar , Restraint, Physical , Reverse Transcriptase Polymerase Chain Reaction , Rifamycins/therapeutic use , Rifaximin , Sequence Analysis, DNA , Stress, Psychological
10.
Inflamm Bowel Dis ; 19(9): 1964-73, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23835442

ABSTRACT

BACKGROUND: Fecal alpha-1-antitrypsin (AAT) clearance has been a marker of clinical disease severity in inflammatory bowel diseases (IBDs) for many years. Although AAT deficiency is more often associated with lung and liver pathologies, AAT-deficient patients with concomitant IBD have been shown to develop more aggressive disease and rapid progression to surgery. Although recent studies have highlighted the pleiotropic anti-inflammatory functions of AAT, including reducing proinflammatory cytokine production and suppressing immune cell activation, its potential therapeutic role in IBD has not been described. METHODS: The therapeutic potential of human AAT administration was assessed in murine models of IBD including new-onset and established chemically induced colitis and spontaneous chronic murine ileitis. Histological assessment of inflammation, cytokine secretion profiling, and flow cytometric evaluation of inflammatory infiltrate were performed in each model. The effect of AAT on intestinal barrier function was also examined both in vitro and in vivo. RESULTS: AAT attenuated inflammation in small and large intestinal IBD models through reduced secretion of proinflammatory cytokines, inflammatory cell infiltration, and reduced tissue injury. AAT also increased intestinal restitution after chemically induced colitis. AAT significantly decreased intestinal permeability in vitro and in vivo as part of a protective mechanism for both acute and chronic models of IBD. CONCLUSIONS: Our findings describe a beneficial role for AAT in IBD models through suppression of cytokine production and enhanced intestinal barrier function. This raises the possibility that AAT supplementation, which has a long history of proven safety, may have a therapeutic effect in human IBD.


Subject(s)
Colitis/prevention & control , Dextran Sulfate/toxicity , Ileitis/prevention & control , alpha 1-Antitrypsin/therapeutic use , Acute Disease , Animals , Cell Membrane Permeability , Chronic Disease , Colitis/chemically induced , Colitis/immunology , Cytokines/metabolism , Flow Cytometry , Humans , Ileitis/chemically induced , Ileitis/immunology , Inflammation/etiology , Inflammation/prevention & control , Mice
11.
Inflamm Bowel Dis ; 19(6): 1285-94, 2013 May.
Article in English | MEDLINE | ID: mdl-23567784

ABSTRACT

BACKGROUND: Enteral nutrition is used to treat a subset of patients with inflammatory bowel diseases. Because dietary factors may contribute to an aggressive immune response toward the intestinal microbiota in the disease susceptible host, we used TNFΔARE/WT mice to study the therapeutic effect of a semisynthetic experimental diet in the pathogenesis of Crohn's disease (CD)-like inflammation in the ileum. METHODS: TNFΔARE/WT mice were fed chow and experimental diets partially fortified with gluten in a dose and time-dependent manner. Histopathology, markers of inflammation, intraepithelial lymphocytes phenotypes, and antigen-specific reactivation of CD4⁺ T cells were determined. RESULTS: TNFΔARE/WT mice being transferred to an experimental diet with 7 but not with 10 or 14 weeks of age were protected from development of Crohn's disease-like ileitis. Although disease-related CD8αß⁺ intraepithelial lymphocytes were increased irrespective of dietary intervention, the protective effect of experimental diet was associated with decreased expression of inflammation markers in ileal tissues. In addition, CD4⁺ T-cell reactivation in bacterial antigen-primed dendritic cell cocultures was not altered between semisynthetic and chow diet-fed TNFΔARE/WT mice, suggesting bacteria-independent mechanisms. Most importantly, gluten-fortified experimental diet induced chronic ileitis in TNFΔARE/WT mice, despite the fact that gluten-derived peptides failed to induce CD4⁺ T-cell activation. Reduced occludin expression levels suggest a negative role of gluten-fortified experimental diet on intestinal barrier integrity. CONCLUSIONS: Crohn's disease-like ileitis can be prevented at early stages of disease development using a semisynthetic experimental diet. Gluten was identified as antigen-independent dietary factor relevant for the induction of chronic inflammation in the small intestine of TNFΔARE/WT mice.


Subject(s)
Antigens/adverse effects , Crohn Disease/prevention & control , Diet , Glutens/adverse effects , Ileitis/prevention & control , Tumor Necrosis Factor-alpha/genetics , Animals , Antigens/immunology , Blotting, Western , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/pathology , Crohn Disease/etiology , Crohn Disease/pathology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Dendritic Cells/pathology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Heterozygote , Ileitis/etiology , Ileitis/pathology , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Mice, Knockout , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Tumor Necrosis Factor-alpha/metabolism
12.
Shock ; 39(4): 373-9, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23376955

ABSTRACT

Interleukin 6 (IL-6) is an inflammatory cytokine known to be elevated in chronic diseases and after insults such as trauma and infection. Although necessary for the development of B cells and Th17 cells, IL-6, at elevated levels, can also cause tissue damage and lead to a rise in inflammation. Previous work in our laboratory has shown that IL-6 is increased both systemically and in multiple organ systems including the ileum after ethanol exposure and burn injury. As this combined insult causes elevated intestinal morphological damage, tight junction protein localization alterations, and phosphorylated myosin light chain levels, we sought to determine the role of IL-6 in these intestinal responses using a model of binge ethanol exposure and burn injury. Interleukin 6 antibody treatment after the combined insult reduced morphological changes in the ileum, bacterial translocation, and phosphorylated myosin light chain levels relative to either injury alone. Zonula occludens protein 1 and occludin localization was also reestablished in wild-type mice given IL-6 antibody after ethanol and burn. Interleukin 6-knockout mice given ethanol and burn injury also had reduced intestinal damage; however, no changes in bacterial translocation or tight junction protein localization were observed as compared with similarly treated wild-type mice. These data suggest that IL-6 may have a role in intestinal tissue damage observed after the combined insult of binge ethanol exposure and burn injury, although complete loss of IL-6 does not seem to be beneficial in this model. Modulation of IL-6 may present a new option for preventing intestinal damage and associated inflammation after a combined insult of ethanol exposure and burn injury.


Subject(s)
Antibodies/pharmacology , Burns/physiopathology , Ethanol/toxicity , Ileitis/prevention & control , Interleukin-6/immunology , Solvents/toxicity , Animals , Bacterial Translocation/drug effects , Bacterial Translocation/immunology , Binge Drinking/immunology , Cytokines/metabolism , Ileitis/chemically induced , Ileitis/physiopathology , Interleukin-6/antagonists & inhibitors , Interleukin-6/deficiency , Mice , Mice, Inbred C57BL , Mice, Knockout , Myosin Light Chains/metabolism , Occludin/metabolism , Zonula Occludens-1 Protein/metabolism
13.
World J Gastroenterol ; 18(40): 5719-28, 2012 Oct 28.
Article in English | MEDLINE | ID: mdl-23155312

ABSTRACT

AIM: To determine whether the carbon monoxide (CO)-releasing molecules (CORM)-liberated CO suppress inflammatory responses in the small intestine of septic mice. METHODS: The C57BL/6 mice (male, n = 36; weight 20 ± 2 g) were assigned to four groups in three respective experiments. Sepsis in mice was induced by cecal ligation and puncture (CLP) (24 h). Tricarbonyldichlororuthenium (II) dimer (CORM-2) (8 mg/kg, i.v.) was administrated immediately after induction of CLP. The levels of inflammatory cytokines [interleukin-1ß (IL-1ß) and tumor necrosis factor-α (TNF-α)] in tissue homogenates were measured with enzyme-linked immunosorbent assay. The levels of malondialdehyde (MDA) in the tissues were determined. The levels of nitric oxide (NO) in tissue homogenate were measured and the expression levels of intercellular adhesion molecule 1 (ICAM-1) and inducible nitric oxide synthase (iNOS) in the small intestine were also assessed. NO and IL-8 levels in the supernatants were determined after the human adenocarcinoma cell line Caco-2 was stimulated by lipopolysaccharide (LPS) (10 g/mL) for 4 h in vitro. RESULTS: At 24 h after CLP, histological analysis showed that the ileum and jejunum from CLP mice induced severe edema and sloughing of the villous tips, as well as infiltration of inflammatory cells into the mucosa. Semi-quantitative analysis of histological samples of ileum and jejunum showed that granulocyte infiltration in the septic mice was significantly increased compared to that in the sham group. Administration of CORM-2 significantly decreased granulocyte infiltration. At 24 h after CLP, the tissue MDA levels in the mid-ileum and mid-jejunum significantly increased compared to the sham animals (103.68 ± 23.88 nmol/mL vs 39.66 ± 8.23 nmol/mL, 89.66 ± 9.98 nmol/mL vs 32.32 ± 7.43 nmol/mL, P < 0.01). In vitro administration of CORM-2, tissue MDA levels were significantly decreased (50.65 ± 11.46 nmol/mL, 59.32 ± 6.62 nmol/mL, P < 0.05). Meanwhile, the tissue IL-1ß and TNF-α levels in the mid-ileum significantly increased compared to the sham animals (6.66 ± 1.09 pg/mL vs 1.67 ± 0.45 pg/mL, 19.34 ± 3.99 pg/mL vs 3.98 ± 0.87 pg/mL, P < 0.01). In vitro administration of CORM-2, tissue IL-1ß and TNF-α levels were significantly decreased (3.87 ± 1.08 pg/mL, 10.45 ± 2.48 pg/mL, P < 0.05). The levels of NO in mid-ileum and mid-jejunum tissue homogenate were also decreased (14.69 ± 2.45 nmol/mL vs 24.36 ± 2.97 nmol/mL, 18.47 ± 2.47 nmol/mL vs 27.33 ± 3.87 nmol/mL, P < 0.05). The expression of iNOS and ICAM-1 in the mid-ileum of septic mice at 24 h after CLP induction significantly increased compared to the sham animals. In vitro administration of CORM-2, expression of iNOS and ICAM-1 were significantly decreased. In parallel, the levels of NO and IL-8 in the supernatants of Caco-2 stimulated by LPS was markedly decreased in CORM-2-treated Caco-2 cells (2.22 ± 0.12 nmol/mL vs 6.25 ± 1.69 nmol/mL, 24.97 ± 3.01 pg/mL vs 49.45 ± 5.11 pg/mL, P < 0.05). CONCLUSION: CORM-released CO attenuates the inflammatory cytokine production (IL-1ß and TNF-α), and suppress the oxidative stress in the small intestine during sepsis by interfering with protein expression of ICAM-1 and iNOS.


Subject(s)
Carbon Monoxide/metabolism , Enteritis/prevention & control , Ileitis/prevention & control , Intestine, Small/drug effects , Jejunal Diseases/prevention & control , Organometallic Compounds/pharmacology , Sepsis/drug therapy , Animals , Caco-2 Cells , Disease Models, Animal , Enteritis/immunology , Enteritis/metabolism , Enteritis/microbiology , Humans , Ileitis/immunology , Ileitis/metabolism , Ileitis/microbiology , Inflammation Mediators/metabolism , Intercellular Adhesion Molecule-1/metabolism , Interleukin-1beta/metabolism , Interleukin-8/metabolism , Intestine, Small/immunology , Intestine, Small/metabolism , Intestine, Small/microbiology , Jejunal Diseases/immunology , Jejunal Diseases/metabolism , Jejunal Diseases/microbiology , Male , Malondialdehyde/metabolism , Mice , Mice, Inbred C57BL , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , Organometallic Compounds/metabolism , Peroxidase/metabolism , Sepsis/immunology , Sepsis/metabolism , Sepsis/microbiology , Time Factors , Tumor Necrosis Factor-alpha/metabolism
14.
PLoS One ; 7(7): e42067, 2012.
Article in English | MEDLINE | ID: mdl-22848704

ABSTRACT

BACKGROUND: We previously showed that the probiotic mixture, VSL#3, prevents the onset of ileitis in SAMP/YitFc (SAMP) mice, and this effect was associated with stimulation of epithelial-derived TNF. The aim of this study was to determine the mechanism(s) of VSL#3-mediated protection on epithelial barrier function and to further investigate the "paradoxical" effects of TNF in preventing SAMP ileitis. METHODS: Permeability was evaluated in SAMP mice prior to the onset of inflammation and during established disease by measuring transepithelial electrical resistance (TEER) on ex vivo-cultured ilea following exposure to VSL#3 conditioned media (CM), TNF or VSL#3-CM + anti-TNF. Tight junction (TJ) proteins were assessed by qRT-PCR, Western blot, and confocal microscopy, and TNFRI/TNFRII expression measured in freshly isolated intestinal epithelial cells (IEC) from SAMP and control AKR mice. RESULTS: Culture with either VSL#3-CM or TNF resulted in decreased ileal paracellular permeability in pre-inflamed SAMP, but not SAMP with established disease, while addition of anti-TNF abrogated these effects. Modulation of the TJ proteins, claudin-2 and occludin, occurred with a significant decrease in claudin-2 and increase in occludin following stimulation with VSL#3-CM or TNF. TNF protein levels increased in supernatants of SAMP ilea incubated with VSL#3-CM compared to vehicle, while IEC-derived TNFR mRNA expression decreased in young, and was elevated in inflamed, SAMP versus AKR mice. CONCLUSIONS: Our data demonstrate that the previously established efficacy of VSL#3 in preventing SAMP ileitis is due to direct innate and homeostatic effects of TNF on the gut epithelium, modulation of the TJ proteins, claudin-2 and occludin, and overall improvement of intestinal permeability.


Subject(s)
Bacteria , Ileitis/metabolism , Ileitis/prevention & control , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Probiotics/pharmacology , Tumor Necrosis Factor-alpha/metabolism , Animals , Gene Expression Regulation/drug effects , Homeostasis/drug effects , Ileitis/microbiology , Ileitis/pathology , Intestinal Mucosa/microbiology , Intestinal Mucosa/pathology , Mice , Permeability/drug effects , Receptors, Tumor Necrosis Factor/metabolism , Tight Junctions/drug effects , Tight Junctions/metabolism
15.
BMC Infect Dis ; 12: 13, 2012 Jan 20.
Article in English | MEDLINE | ID: mdl-22264229

ABSTRACT

BACKGROUND: Severe Clostridium difficile toxin-induced enteritis is characterized by exuberant intestinal tissue inflammation, epithelial disruption and diarrhea. Adenosine, through its action on the adenosine A2A receptor, prevents neutrophillic adhesion and oxidative burst and inhibits inflammatory cytokine production. Alanyl-glutamine enhances intestinal mucosal repair and decreases apoptosis of enterocytes. This study investigates the protection from enteritis by combination therapy with ATL 370, an adenosine A2A receptor agonist, and alanyl-glutamine in a rabbit and murine intestinal loop models of C. difficile toxin A-induced epithelial injury. METHODS: Toxin A with or without alanyl-glutamine was administered intraluminally to rabbit ileal or murine cecal loops. Animals were also given either PBS or ATL 370 parenterally. Ileal tissues were examined for secretion, histopathology, apoptosis, Cxcl1/KC and IL-10. RESULTS: ATL 370 decreased ileal secretion and histopathologic changes in loops treated with Toxin A. These effects were reversed by the A2A receptor antagonist, SCH 58261, in a dose-dependent manner. The combination of ATL 370 and alanyl-glutamine significantly further decreased ileal secretion, mucosal injury and apoptosis more than loops treated with either drug alone. ATL 370 and alanyl-glutamine also decreased intestinal tissue KC and IL-10. CONCLUSIONS: Combination therapy with an adenosine A2A receptor agonist and alanyl-glutamine is effective in reversing C. difficile toxin A-induced epithelial injury, inflammation, secretion and apoptosis in animals and has therapeutic potential for the management of C. difficile infection.


Subject(s)
Adenosine A2 Receptor Antagonists/administration & dosage , Bacterial Toxins/toxicity , Clostridioides difficile/pathogenicity , Dipeptides/administration & dosage , Enterotoxins/toxicity , Ileitis/pathology , Typhlitis/pathology , Animals , Apoptosis , Disease Models, Animal , Histocytochemistry , Ileitis/prevention & control , Male , Mice , Mice, Inbred C57BL , Rabbits , Treatment Outcome , Typhlitis/prevention & control
17.
Eur J Nutr ; 50(4): 261-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-20936479

ABSTRACT

BACKGROUND: There are substantial evidences suggesting that probiotics can protect the gastrointestinal tract against inflammatory or infectious episodes. The effects of oral treatment with viable or heat-killed cells of Saccharomyces boulardii (Sb) on bacterial translocation, intestinal permeability, histological aspect of the ileum, and some immunological parameters were evaluated in a murine intestinal obstruction (IO) model. RESULTS: Bacterial translocation and intestinal permeability in the IO group were significantly higher when compared to a Sham group (p < 0.05). Pretreatment with both viable and heat-killed S. boulardii prevented these increases, and the data obtained for IO + Sb and IO + heat-killed Sb groups were similar to those observed in the Sham group (p > 0.05). Histological analysis showed preservation of the ileum mucosa in mice that received both forms of the yeast when compared to the lesions observed in the IO group. The levels of serum interleukin (IL)-10 and intestinal secretory immunoglobulin A (sIgA) were higher in the animals that received both yeast treatments when compared to those from IO and Sham groups. CONCLUSION: Oral treatment with viable or heat-killed cells of S. boulardii maintained intestinal integrity and modulated the immune system in a murine IO model, preventing bacterial translocation and intestinal lesions.


Subject(s)
Bacterial Translocation , Ileitis/prevention & control , Intestine, Small/physiopathology , Probiotics/therapeutic use , Saccharomyces/physiology , Animals , Eating , Escherichia coli/physiology , Hot Temperature , Ileitis/immunology , Ileitis/pathology , Ileitis/physiopathology , Ileum/immunology , Ileum/pathology , Immunoglobulin A, Secretory/analysis , Inflammation Mediators/blood , Intestinal Obstruction/immunology , Intestinal Obstruction/pathology , Intestinal Obstruction/physiopathology , Intestine, Small/immunology , Intestine, Small/pathology , Male , Mice , Microbial Viability , Permeability , Random Allocation , Severity of Illness Index , Time Factors , Weight Gain
18.
Gut ; 60(3): 325-33, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21076126

ABSTRACT

BACKGROUND: Iron replacement therapy is a common treatment in patients with anaemia and Crohn's disease, but oral iron supplements are less tolerated. The pathogenesis of Crohn's disease is attributed to intestinal bacteria and environmental factors that trigger disease in a genetically predisposed host. The aim of this study was to characterise the interrelationship between luminal iron sulfate, systemic iron, the gut microbiota and the development of chronic ileitis in a murine model of Crohn's disease. METHODS: Wild type (WT) and heterozygous TNF(ΔARE/WT) mice were fed with an iron sulfate containing or iron sulfate free diet in combination with intraperitoneal control injections or iron injections for 11 weeks. RESULTS: TNF(ΔARE/WT) mice develop severe inflammation of the distal ileum but remained completely healthy when transferred to an iron sulfate free diet, even if iron was systemically repleted. Absence of luminal iron sulfate reduced cellular markers of endoplasmic reticulum (ER) stress responses and pro-apoptotic mechanisms in the ileal epithelium. Phenotype or reactivity of major effector intraepithelial CD8αß(+) T cells were not altered in the absence of luminal iron. Interestingly, ER stress mechanisms sensitised the small intestinal epithelial cell (IEC) line Mode-K to cytotoxic function of effector T cells from TNF(ARE/WT) mice. Pyrosequencing of 16S rRNA tags of the caecal microbiota revealed that depletion of luminal iron sulfate induced significant compositional alterations, while total microbial diversity (Shannon's diversity index) and number of total operational taxonomic units were not affected. CONCLUSION: This study showed that an iron sulfate free diet in combination with systemic iron repletion prevents the development of chronic ileitis in a murine model of Crohn's disease. Luminal iron may directly affect IEC function or generate a pathological milieu in the intestine that triggers epithelial cell stress-associated apoptosis through changes in microbial homeostasis. These results suggest that oral replacement therapy with iron sulfate may trigger inflammatory processes associated with progression of Crohn's disease-like ileitis.


Subject(s)
Cecum/microbiology , Crohn Disease/prevention & control , Ileitis/prevention & control , Iron Deficiencies , Animals , Apoptosis/drug effects , Apoptosis/physiology , Cell Line , Chronic Disease , Coculture Techniques , Crohn Disease/metabolism , Crohn Disease/microbiology , Disease Models, Animal , Endoplasmic Reticulum/physiology , Ileitis/metabolism , Ileitis/microbiology , Ileum/pathology , Intestinal Mucosa/pathology , Iron/pharmacology , Iron/physiology , Iron, Dietary/administration & dosage , Mice , Mice, Inbred C57BL , Stress, Physiological/drug effects , Stress, Physiological/physiology , T-Lymphocytes, Cytotoxic/immunology
19.
Gastroenterology ; 139(2): 542-52, 552.e1-3, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20398664

ABSTRACT

BACKGROUND & AIMS: Clostridium difficile-associated disease (CDAD) is the leading cause of nosocomial diarrhea in the United States. C difficile toxins TcdA and TcdB breach the intestinal barrier and trigger mucosal inflammation and intestinal damage. The inflammasome is an intracellular danger sensor of the innate immune system. In the present study, we hypothesize that TcdA and TcdB trigger inflammasome-dependent interleukin (IL)-1beta production, which contributes to the pathogenesis of CDAD. METHODS: Macrophages exposed to TcdA and TcdB were assessed for IL-1beta production, an indication of inflammasome activation. Macrophages deficient in components of the inflammasome were also assessed. Truncated/mutated forms of TcdB were assessed for their ability to activate the inflammasome. The role of inflammasome signaling in vivo was assessed in ASC-deficient and IL-1 receptor antagonist-treated mice. RESULTS: TcdA and TcdB triggered inflammasome activation and IL-1beta secretion in macrophages and human mucosal biopsy specimens. Deletion of Nlrp3 decreased, whereas deletion of ASC completely abolished, toxin-induced IL-1beta release. TcdB-induced IL-1beta release required recognition of the full-length toxin but not its enzymatic function. In vivo, deletion of ASC significantly reduced toxin-induced inflammation and damage, an effect that was mimicked by pretreatment with the IL-1 receptor antagonist anakinra. CONCLUSIONS: TcdA and TcdB trigger IL-1beta release by activating an ASC-containing inflammasome, a response that contributes to toxin-induced inflammation and damage in vivo. Pretreating mice with the IL-1 receptor antagonist anakinra afforded the same level of protection that was observed in ASC-/- mice. These data suggest that targeting inflammasome or IL-1beta signaling may represent new therapeutic targets in the treatment of CDAD.


Subject(s)
Clostridioides difficile/pathogenicity , Ileitis/immunology , Ileum/immunology , Immunity, Innate , Inflammation Mediators/metabolism , Interleukin-1beta/metabolism , Macrophages/immunology , Animals , Apoptosis Regulatory Proteins , Bacterial Proteins/genetics , Bacterial Toxins/genetics , Biopsy , CARD Signaling Adaptor Proteins , Carrier Proteins/genetics , Carrier Proteins/metabolism , Caspase 1/metabolism , Cell Line , Clostridioides difficile/genetics , Cytoskeletal Proteins/deficiency , Cytoskeletal Proteins/genetics , Disease Models, Animal , Endocytosis , Endosomes/immunology , Endosomes/microbiology , Enterotoxins/genetics , Humans , Ileitis/microbiology , Ileitis/pathology , Ileitis/prevention & control , Ileum/drug effects , Ileum/microbiology , Ileum/pathology , Immunity, Innate/drug effects , Interleukin 1 Receptor Antagonist Protein/pharmacology , Macrophages/drug effects , Macrophages/microbiology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Mutation , NLR Family, Pyrin Domain-Containing 3 Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...